Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 4/20 | 0.69 |
| ▸ | FABP5 | Q01469 | 4/20 | 0.69 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | DHFR | P00374 | 9/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14916666 | 0.85 | FABP4 (0.56) | FABP4FABP5RORCALDH1A1HPGD | |
| SCHEMBL14927287 | 0.82 | FABP4 (0.49) | FABP4FABP5NPBWR1DHFRDGAT1 | |
| SCHEMBL14916584 | 0.82 | FABP4 (1.00) | FABP4FABP5RORCDHFRESR1 | |
| SCHEMBL14927276 | 0.81 | FABP4 (0.70) | FABP4FABP5RORCALDH1A1HPGD | |
| SCHEMBL14916566 | 0.81 | FABP4 (0.49) | FABP4FABP5NPBWR1RORCDGAT1 | |
| SCHEMBL14927280 | 0.79 | FABP4 (0.49) | FABP4FABP5RORCDHFRALDH1A1 | |
| SCHEMBL14927281 | 0.76 | FABP4 (0.46) | FABP4FABP5NPBWR1DGAT1KCNH2 | |
| SCHEMBL14916653 | 0.76 | FABP4 (0.68) | FABP4FABP5SMN1; SMN2ESR1KDM4E | |
| SCHEMBL14927285 | 0.75 | FABP4 (0.48) | FABP4FABP5NPBWR1DGAT1KCNH2 | |
| SCHEMBL14916701 | 0.75 | FABP4 (0.70) | FABP4FABP5NPBWR1RORCDGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11229624-B2 | FABP4 as a therapeutic target in skin diseases | TICURE LTD. (IL) | 2022-01-25 | — | — | US | disclosed |
| US-20200138779-A1 | FABP4 AS A THERAPEUTIC TARGET IN SKIN DISEASES | TICURE LTD. (IL) | 2020-05-07 | — | — | US | disclosed |
| US-9809599-B2 | Aryl-quinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-9809599-B2 | Aryl-quinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-11-07 | — | — | US | disclosed |
| EP-2773619-B1 | NEW ARYL-QUINOLINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2016-11-16 | — | — | EP | disclosed |
| US-20160060270-A1 | New Aryl-Quinoline Derivatives | HOFFMANN-LA ROCHE INC. | 2016-03-03 | — | — | US | disclosed |
| US-20160060270-A1 | New Aryl-Quinoline Derivatives | HOFFMANN-LA ROCHE INC. | 2016-03-03 | — | — | US | disclosed |
| US-9199938-B2 | Aryl-quinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-9199938-B2 | Aryl-quinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2015-12-01 | — | — | US | disclosed |
| WO-2013064465-A1 | NEW ARYL-QUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-05-10 | — | — | WO | disclosed |
| US-20130116234-A1 | ARYL-QUINOLINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116234-A1 | ARYL-QUINOLINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116234-A1 | ARYL-QUINOLINE DERIVATIVES | FABP1, FABP4, FABP5 | FABP4 2/4885FABP5 3/4885NPBWR1 922/4885 |
| US-20160060270-A1 | New Aryl-Quinoline Derivatives | FABP1, FABP4, FABP5 | FABP4 2/4885FABP5 3/4885NPBWR1 858/4885 |
| US-11229624-B2 | FABP4 as a therapeutic target in skin diseases | FABP4, FABP2, FABP1 | FABP4 1/4885FABP5 4/4885NPBWR1 1756/4885 |
| US-20200138779-A1 | FABP4 AS A THERAPEUTIC TARGET IN SKIN DISEASES | FABP4, FABP2, FABP1 | FABP4 1/4885FABP5 4/4885NPBWR1 1756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.